Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

OBJECTIVES: Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating spontaneous autoimmune diabetes in nonobese...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Tingting, Phung, Amber‐Lee, Jhala, Gaurang, Trivedi, Prerak, Principe, Nicola, De George, David J, Pappas, Evan G, Litwak, Sara, Sanz‐Villanueva, Laura, Catterall, Tara, Fynch, Stacey, Boon, Louis, Kay, Thomas W, Chee, Jonathan, Krishnamurthy, Balasubramanian, Thomas, Helen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618467/
https://www.ncbi.nlm.nih.gov/pubmed/36325490
http://dx.doi.org/10.1002/cti2.1425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618467/
https://www.ncbi.nlm.nih.gov/pubmed/36325490
http://dx.doi.org/10.1002/cti2.1425

Ejemplares similares